

Zydus Cadila registers 33% increase in Operating Net Profit in Q2

Ahmedabad, 22nd October 2008

During the second quarter ended September 30, 2008, Zydus Cadila reported a total income of Rs. 741 crores, up by 22% from Rs. 610 crores in the corresponding quarter of the previous year, on a consolidated basis. The PBIDT was up by 16% to Rs. 152 crores during the quarter from Rs. 132 crores in the corresponding period last year. The operating net profit was up by 33% to Rs. 108 crores from Rs. 82 crores in the second quarter of 2007-08.

During the quarter, the company's subsidiaries in France and US registered a strong performance. Zydus France SAS, which currently markets over 120 generic presentations, registered 27% growth in sales. During the quarter, the company received approvals for 6 dossiers for new products and 3 site transfer applications from the French regulatory authority AFSSAPS.

In the US, the company's sales grew by 28%. During the quarter, the company received approvals from the USFDA for Bromocriptine Mesylate Capsules and Ramipril Capsules. The group filed 5 additional DMFs and 3 more ANDAs this quarter taking the total to 64 DMFs and 79 ANDA filings, of which 41 have been approved so far.

During the quarter, the company entered into an agreement with WHO to explore a possible collaboration in the development of a cocktail for the treatment of rabies, through the use of monoclonal antibodies (MAbs), the next-generation biologicals.
